BioCentury | Jan 12, 2021
Emerging Company Profile

Atalanta’s next-gen RNAi branches deeper into brain, hooks Biogen and Genentech

A rush of interest following the publication of Atalanta’s brain-optimized siRNA tech enabled the UMass Medical School spinout to launch with two high-profile partners in hand. Atalanta Therapeutics Inc....
BioCentury | Dec 5, 2020
Product Development

Bispecifics spring ahead at this year’s ASH, SITC

Bispecific antibodies are starting to diverge from CAR Ts as they venture into new targets and indications in the clinic.  First-generation T cell-engaging bispecific antibodies have mirrored the...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

As targeted protein degradation grows up, the field is going after harder targets and new mechanisms of action. Over the last year, a series of Phase I/II readouts from front-runner Arvinas Inc. (NASDAQ:ARVN),...
BioCentury | Sep 22, 2020
Politics, Policy & Law

Azar’s memo & biotech’s deals: a BioCentury podcast

A controversy over a memo from HHS Secretary Alex Azar has further exposed the fraught atmosphere in Washington over claims that FDA and other agencies have been politicized amid the global pandemic. In the latest BioCentury This...
BioCentury | Sep 18, 2020
Finance

With details on lead sialoglycan degrader in place, Palleon raises $100M series B

Having nominated a lead program, identified top indications and sorted out manufacturing, Palleon raised a $100 million series B round to bring its enzymatic sialoglycan degrader to the clinic for cancer....
BioCentury | Sep 16, 2020
Politics, Policy & Law

Trump administration sends mixed messages on COVID-19 vaccine availability

Leaders of Operation Warp Speed and Trump administration officials Wednesday morning released plans for the distribution of hundreds of millions of doses of COVID-19 vaccines, outlined how access will be prioritized in the case of...
BioCentury | Sep 9, 2020
Politics & Policy

Impact of China’s export restrictions on biopharma dealmaking likely limited, at least for now

While a handful of revisions to China’s export restrictions apply to technologies in the biopharma sector, their effect on cross-border dealmaking is likely limited given that many domestic companies are built on an in-licensing rather...
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

A growing list of cytokine therapies have been designed to boost cytotoxic immune responses against cancer while sidestepping the limitations of past candidates by controlling where the molecules do and...
BioCentury | Aug 28, 2020
Deals

BARDA enlisting start-ups in fight against COVID-19 via JLABS collaboration

A collaboration between JLABS and BARDA gives the government agency access to start-ups that it needs to fast track new, innovative COVID-19 therapies and diagnostics it otherwise would struggle...
BioCentury | Jul 14, 2020
Deals

Roche deal clears path for Blueprint’s financial independence

In the year’s largest licensing deal thus far, Blueprint has secured the resources it needs to sustain itself financially while gaining access to Roche’s diagnostic capabilities, a key driver for commercializing its targeted therapies for...
Items per page:
1 - 10 of 1663
BioCentury | Jan 12, 2021
Emerging Company Profile

Atalanta’s next-gen RNAi branches deeper into brain, hooks Biogen and Genentech

A rush of interest following the publication of Atalanta’s brain-optimized siRNA tech enabled the UMass Medical School spinout to launch with two high-profile partners in hand. Atalanta Therapeutics Inc....
BioCentury | Dec 5, 2020
Product Development

Bispecifics spring ahead at this year’s ASH, SITC

Bispecific antibodies are starting to diverge from CAR Ts as they venture into new targets and indications in the clinic.  First-generation T cell-engaging bispecific antibodies have mirrored the...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

As targeted protein degradation grows up, the field is going after harder targets and new mechanisms of action. Over the last year, a series of Phase I/II readouts from front-runner Arvinas Inc. (NASDAQ:ARVN),...
BioCentury | Sep 22, 2020
Politics, Policy & Law

Azar’s memo & biotech’s deals: a BioCentury podcast

A controversy over a memo from HHS Secretary Alex Azar has further exposed the fraught atmosphere in Washington over claims that FDA and other agencies have been politicized amid the global pandemic. In the latest BioCentury This...
BioCentury | Sep 18, 2020
Finance

With details on lead sialoglycan degrader in place, Palleon raises $100M series B

Having nominated a lead program, identified top indications and sorted out manufacturing, Palleon raised a $100 million series B round to bring its enzymatic sialoglycan degrader to the clinic for cancer....
BioCentury | Sep 16, 2020
Politics, Policy & Law

Trump administration sends mixed messages on COVID-19 vaccine availability

Leaders of Operation Warp Speed and Trump administration officials Wednesday morning released plans for the distribution of hundreds of millions of doses of COVID-19 vaccines, outlined how access will be prioritized in the case of...
BioCentury | Sep 9, 2020
Politics & Policy

Impact of China’s export restrictions on biopharma dealmaking likely limited, at least for now

While a handful of revisions to China’s export restrictions apply to technologies in the biopharma sector, their effect on cross-border dealmaking is likely limited given that many domestic companies are built on an in-licensing rather...
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

A growing list of cytokine therapies have been designed to boost cytotoxic immune responses against cancer while sidestepping the limitations of past candidates by controlling where the molecules do and...
BioCentury | Aug 28, 2020
Deals

BARDA enlisting start-ups in fight against COVID-19 via JLABS collaboration

A collaboration between JLABS and BARDA gives the government agency access to start-ups that it needs to fast track new, innovative COVID-19 therapies and diagnostics it otherwise would struggle...
BioCentury | Jul 14, 2020
Deals

Roche deal clears path for Blueprint’s financial independence

In the year’s largest licensing deal thus far, Blueprint has secured the resources it needs to sustain itself financially while gaining access to Roche’s diagnostic capabilities, a key driver for commercializing its targeted therapies for...
Items per page:
1 - 10 of 1663